Teva issues about $4.9B in notes; shifts ADS to NYSE
Teva Pharmaceutical Industries is refinancing debt with roughly $4.9B/€1.5B in notes and converting its ADS into ordinary shares for NYSE trading.
5B in notes to refinance debt while shifting ADS to ordinary shares for NYSE trading. The company also cited strong commercial momentum from AUSTEDO, AJOVY and UZEDY, biosimilar expansion and positiv…